Introduction to the canadian scientific advisory committee on respiratory and allergy therapies: In vivo evaluation for clinical testing in COPD and asthma therapy using generics

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 25, Issue 4, 2012, Pages 204-208

  Mayers, Irvin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

asthma; COPD; generic; inflammation; metered dose inhaler

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT;

ADVISORY COMMITTEE; AREA UNDER THE CURVE; ASTHMA; BIOEQUIVALENCE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; HUMAN; IN VIVO STUDY; METERED DOSE INHALER; OUTCOME ASSESSMENT; PHENOTYPE; PUBLICATION; RESPIRATORY TRACT INFLAMMATION; REVIEW;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADVISORY COMMITTEES; ASTHMA; CANADA; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, GENERIC; ENDPOINT DETERMINATION; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS;

EID: 84864677151     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2011.0913     Document Type: Review

References (26)

1. Committee on Drugs: Inactive ingredients in pharmaceutical products: update. Pediatrics. 1997;99:268-278.
2. The American Lung Association Asthma Clinical Research Centers: Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med. 2007;356:2027-2039.
3. Martinez FD, Chinchilli VM, Morgan WJ, Boehmer SJ, Lemanske RF Jr, Mauger DT, Strunk RC, Szefler SJ, Zeiger RS, Bacharier LB, Bade E, Covar RA, Friedman NJ, Guilbert TW, Heidarian-Raissy H, Kelly HW, Malka-Rais J, Mellon MH, Sorkness CA, and Taussig L: Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebocontrolled trial. Lancet. 2011;377:650-657.
4. Nair PK, and Hargreave FE: The use of sputum cell counts to evaluate asthma medications. Br J Clin Pharmacol. 2001;52: 121-128.
5. Saha SK, Berry MA, Parker D, Siddiqui S, Morgan A, May R, Monk P, Bradding P, Wardlaw AJ, Pavord ID, and Brightling CE: Increased sputum and bronchial biopsy IL-13 expression in severe asthma. J Allergy Clin Immunol. 2008;121:685-691.
6. Smith AD, Cowan JO, Brassett KP, Herbison GP, and Taylor DR: Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163-2173.
7. Cockcroft DW, Davis BE, and Todd DC: Methacholine challenge: comparison of two methods. Chest. 2005;127:839-844.
8. Juniper EF, Johnston PR, Borkhoff CM, Guyatt GH, Boulet LP, and Haukioja A. Quality of life in asthma clinical trials: Comparison of salmeterol and salbutamol. Am J Respir Crit Care Med. 1995;151:66-70.
9. Therapeutic Products Directorate, Health Canada: Submission Requirements for Subsequent Market Entry Inhaled Corticosteroid Products for Use in the Treatment of Asthma. 2007. Available at: http://www.hc-sc.gc.ca/dhp-mps/ prodpharma/applic-demande/guide-ld/inhal-corticost-eng .php
10. Therapeutic Products Directorate, Health Canada: Guidance for Industry Pharmaceutical Quality of Inhalation and Nasal Products. 2006. Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/chem/ inhalationnas-eng .php
11. Jatakanon A, Lim S, Chung KF, and Barnes PJ: An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J. 1998;12:1084-1088.
12. Jatakanon A, Kharitonov S, Lim S, and Barnes PJ: Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999;54:108-114.
13. Martin RJ, Szefler SJ, King TS, Kraft M, Homer B, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fahy JV, Israel E, Lazarus SC, Lemanske RF Jr, Leone FT, Pesola GR, Peters SP, Sorkness CA, Szwejbka LA, and Wechsler ME: The predicting response to inhaled corticosteroid efficacy (PRICE) trial. J Allergy Clin Immunol. 2007;119:73-80.
14. Szefler SJ, Martin RJ, King TS, Boushey HA, Cherniack RM, Chinchilli VM, Craig TJ, Dolovich M, Drazen JM, Fagan JK, Fahy JV, Fish JE, Ford JG, Israel E, Kiley J, Kraft M, Lazarus SC, Lemanske RF Jr, Mauger E, Peters SP, and Sorkness CA: Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109: 410-418.
15. Jatakanon A, Lim S, Chung KF, Barnes PJ. An inhaled steroid improves markers of airway inflammation in patients with mild asthma. Eur Respir J. 1998;12:1084-1088.
16. Pizzichini MMM, Pizzichini E, Clelland L, Efthimiadis A, Mahony J, Dolovich J, and Hargreave FE: Sputum in severe exacerbations of asthma kinetics of inflammatory indices after prednisone treatment. Am J Respir Crit Care Med. 1997;155:1501-1508.
17. Kelly MM, Leigh R, Jayaram L, Goldsmith CH, Parameswaran K, and Hargreave FE: Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol. 2006;117:989-994.
18. Pavord ID, Brightling CE, Woltmann G, and Wardlaw AJ: Non-eosinophilic corticosteroid unresponsive asthma. Lancet. 1999;353:2213-2214.
19. Gauvreau GM, Boulet L-P, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong ML, Watson RM, Renzi PM, and O'Byrne PM: Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses. Am J Respir Crit Care Med. 2008;177:952-958.
20. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, Ford G, Gervais A, Goldstein R, Hodder R, Kaplan A, Keenan S, Lacasse Y, Maltais F, Road J, Rocker G, Sin D, Sinuff T, Voduc N: State of the Art Compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease Can Respir J. 2007;14(Suppl B):5B-32B.
21. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, and Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
22. Tashkin DP, Celli B, Senn S, Burkhart D, Menjoge S, and Decramer M, for the UPLIFT Study Investigators: A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359:1543-1554.
23. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JAD, Korducki L, Cassino C, and Kesten S: Prevention of exacerbations of chronic obstructive pulmonary disease with Tiotropium, a once-daily inhaled anticholinergic bronchodilator. A randomized trial. Ann Intern Med. 2005;143:317-326.
24. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Molken MP, Stockley R, Sullivan SD, Wedzicha JA, and Wouters EF, on behalf of the American Thoracic Society/European Respiratory Society Task Force on outcomes of COPD Outcomes for COPD pharmacological trials: From lung function to biomarkers. Eur Respir J. 2008;31:416-468.
25. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, and Dorinsky PM, the SMART Study Group: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
26. Hill K, Goldstein RS, Guyatt GH, Blouin M, Tan WC, Davis LL, Heels-Ansdell DM, Erak M, Bragaglia PJ, Tamari IE, Hodder R, and Stanbrook MB: Prevalence and underdiagnosis of chronic obstructive pulmonary disease among patients at risk in primary care. Can Med Assoc J. 2010;182:673-678.